Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment

Journal of Neuro-Oncology

Volumn 100, Issue 2, 2010, Pages 225-232

  Kawai, Nobuyuki ^a   Zhen, Hai Ning ^a,b   Miyake, Keisuke ^a   Yamamaoto, Yuka ^c   Nishiyama, Yoshihiro ^c   Tamiya, Takashi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

18F fluorodeoxyglucose (FDG); Positron emission tomography (PET); Primary central nervous system lymphoma; Prognosis

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; DRUG UPTAKE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VASCULARIZATION;

AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 79952194843     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0182-0     Document Type: Article

References (35)

1. Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T (2006) Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 58:394-403 (Pubitemid 43729064)
2. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L (2006) [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol 27:1432-1437 (Pubitemid 44260122)
3. Corry J, Smith JG, Wirth A, Quong G, Liew KH (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41:615-620 (Pubitemid 28275092)
4. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648 (Pubitemid 36025280)
5. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kressler RM, Johnston GS, Manning RG, Wolf AP (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329 (Pubitemid 13218489)
6. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272 (Pubitemid 46606155)
7. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570-4574 (Pubitemid 46630953)
8. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259-268 (Pubitemid 29488384)
9. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18f]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376-1381 (Pubitemid 41129604)
10. Haldorsen IS, Kråkenes J, Krossnes BK, Mella O, Espeland A (2009) CT and MRI imaging features of primary central nervous system lymphoma in Norway, 1989-2003. Am J Neuroradiol 30:744-751
11. Hartmann M, Heiland S, Harting I, Tronnier VM, Sommer C, Ludwig R, Sartor K (2003) Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338:119-122 (Pubitemid 36140152)
12. 18F- fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009-2017
13. Hayabuchi N, Shibamoto Y, Onizuka Y (1999) Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys 44:265-272 (Pubitemid 29205021)
14. Karantanis D, O'Neill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA (2007) 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 28:834-841 (Pubitemid 47494107)
15. 18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis. Ann Nucl Med 19:685-690
16. Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32:52-59 (Pubitemid 40142778)
17. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's Disease. J Nucl Med 43:1018-1027 (Pubitemid 34847924)
18. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD (2003) Methyl-[11C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868-873 (Pubitemid 36734206)
19. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fluorodeoxy glucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972-1980
20. Liao W, Liu Y, Wang X, Jiang X, Tang B, Fang J, Chen C, Hu Z (2009) Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast enhanced perfusion magnetic resonance imaging. Acta Radiol 50:217-225
21. 18F-FDG PET for prediction of prognosis in patients with diffuse large Bcell lymphoma: SUV-base assessment versus visual analysis. J Nucl Med 48:1626-1632
22. Mohile NA, DeAngelis LM, Abrey LE (2008) Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 6:818-820, 840
23. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ (1992) Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17
24. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satho K, Ohkawa M (2007) Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 34:78-86 (Pubitemid 44885557)
25. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519-526 (Pubitemid 30078533)
26. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS (1997) PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 38:1575-1583 (Pubitemid 27443958)
27. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227-237 (Pubitemid 37203463)
28. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, Linnebank M, Joe A, Bucerius J, Biersack HJ, Pels H (2006) FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 33:164-168 (Pubitemid 43152883)
29. Roelcke U, Leenders KL (1999) Positron emission tomography in patients with primary CNS lymphoma. J Neurooncol 43:231-236 (Pubitemid 29488380)
30. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC (1992) Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 33:532-536
31. Shibamoto Y, Ogino H, Suzuki G, Takemoto M, Araki N, Isobe K, Tsuchida E, Nakamura K, Kenjo M, Suzuki K, Hosono M, Tokumaru S, Ishihara S, Kato E, Ii N, Hayabuchi N (2008) Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004. Neuro Oncol 10:560-568
32. Takeuchi H, Matsuda K, Kitai R, Sato K, Kubota T (2007) Angiogenesis in primary central nervous system lymphoma (PCNSL). J Neurooncol 84:141-145 (Pubitemid 47202122)
33. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K (2002) Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 26:185-190 (Pubitemid 34233362)
34. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 31:22-28 (Pubitemid 38133537)
35. Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC, Wang XL (2005) Surviving expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775-2783 (Pubitemid 41798288)